XFOR · X4 Pharmaceuticals, Inc
$3.35
+0.10 (+3.08%)
At close · Oct 28
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. Although the Company has an approved drug product, licensing and sales of the Company's drug product over the next 12 months will not be sufficient to fund the Company's operating expenses. Since inception, the Company has incurred significant operating losses and negative cash flows from operations, and the Company expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future. For the six months ended June 30, 2026, the Company's net loss was $36.4 million and net cash used in operating activities was $40.4 million. As of June 30, 2026, the Company had $208.0 million of cash, cash equivalents and short-term marketable securities, and an accumulated deficit of $631.0 million. Based on its current operating plan, the Company believes (a) that its current cash, cash equivalents and short-term marketable securities will be sufficient to fund its operations and debt obligations for at least the next 12 months and (b) it will continue to comply with all covenants under the Hercules Loan Agreement, as defined and further described in Note 9, through at least the 12-month period from the issuance date of these condensed consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$329.66M
Shares
99.15M
Volume · Oct 28
437.43K
Avg daily vol (3M)
853.45K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.25
Open$3.25
Day$3.05–3.30
52W close$2.45–4.67
Avg vol 30d888K
Short int7.5M · 7.6% float · 12.5d
Short vol35%
Last earningsMay 1, 2025
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
call held May 1, 2025
Latest filings
8-K
Entered into a material agreement
·
filed Oct 8, 2026
X4 Pharmaceuticals entered a loan facility of up to $150.0 million with K2 HealthVentures LLC; $80.0 million funded October 7, 2026, repaid $78.7 million of Hercules obligations, while up to $70.0 million remains subject to lender approval.
Read the 8-K
10-Q
filed Aug 6, 2026
Read the 10-Q
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$8.80M
Trailing 12 months
Net income (TTM)
−$90.14M
Trailing 12 months
Revenue growth YoY
+41.2%
Year over year
Operating margin
-998.9%
Trailing 12 months
P / E (TTM)
2.6
Trailing earnings · reciprocal yield 39.1%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$120.09M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,604.4%
Year over year · more shares
Price change (1Y)
-13.1%
Trailing year
Short interest
7.6%
Latest settlement · 12.5 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 17.5 · elevated
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−15%
below
Price vs 50-day avg
−4%
below
RSI (14)
57
neutral
MACD trend
Positive
52-week position
36%
mid-range
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−26%
trailing
YTD return
−19%
this year
Relative strength
−31%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
8 of 90 funds reported for Sep 30 · net -8.8K sh shares · +3 new
Insider flow
Distributing
Net -$341.8K over 90 days · 75% sells
Short interest
Falling
7.56% of float · ▼ -1.3% MoM · 12.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
90 holders — mid 3-yr range
Squeeze score
78
high risk · 0–100
Fundamentals
Revenue growth
+150%
Y/Y
EPS growth
+67%
Y/Y
Free cash flow
$-85.9M
Balance sheet
$44.6M
net cash
Quant / Vol
risk profile
Volatility
73%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
6.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−15%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
36%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
8 of 90 funds reported for Sep 30 · net -8.8K sh shares · +3 new
Insider flow
Distributing
Net -$341.8K over 90 days · 75% sells
Short interest
Falling
7.56% of float · ▼ -1.3% MoM · 12.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
90 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 36%
Range high $5
vs 200-day avg -15%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Direct research and development program expenses (X4P-001, mavorixafor) | $10.43M | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XFOR
this stock
X4 Pharmaceuticals, Inc
|
$329.66M | -18.8% | +150.0% | — | 7.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$134.22B | +14.9% | +46.2% | 30.8 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.02B | +5.7% | +20.8% | 20.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.03B | +605.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 8, 2026
- This year
- 15
X4 Pharmaceuticals entered a loan facility of up to $150.0 million with K2 HealthVentures LLC; $80.0 million funded October 7, 2026, repaid $78.7 million of Hercules obligations, while up to $70.0 million remains subject to lender approval.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XFOR | +7.6% | +12.1% | -25.8% | +12.1% | -18.8% |
| SPY | +0.1% | +0.7% | +4.9% | +0.9% | +12.9% |
| vs SPY | +7.5% | +11.4% | -30.7% | +11.2% | -31.6% |